SNSE Key Statistics, Chart & Performance
The current stock price of SNSE is 8.45 USD. In the past month the price decreased by -9.87%. In the past year, price decreased by -21.93%.
SNSE Latest News, Press Relases and Analysis
SNSE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About SNSE
Company Profile
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
Company Info
SENSEI BIOTHERAPEUTICS INC
1405 Research Blvd, Suite 125
Rockville MARYLAND 20850 US
CEO: John Celebi
Employees: 15
Phone: 12402438000
SENSEI BIOTHERAPEUTICS INC / SNSE FAQ
Can you describe the business of SENSEI BIOTHERAPEUTICS INC?
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.
What is the current price of SNSE stock?
The current stock price of SNSE is 8.45 USD. The price decreased by -1.74% in the last trading session.
Does SENSEI BIOTHERAPEUTICS INC pay dividends?
SNSE does not pay a dividend.
How is the ChartMill rating for SENSEI BIOTHERAPEUTICS INC?
SNSE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for SNSE stock?
SENSEI BIOTHERAPEUTICS INC (SNSE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.13).
Who owns SENSEI BIOTHERAPEUTICS INC?
You can find the ownership structure of SENSEI BIOTHERAPEUTICS INC (SNSE) on the Ownership tab.
SNSE Technical Analysis
SNSE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SNSE. The financial health of SNSE is average, but there are quite some concerns on its profitability.
SNSE Financial Highlights
Over the last trailing twelve months SNSE reported a non-GAAP Earnings per Share(EPS) of -19.13. The EPS increased by 19.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.39% | ||
| ROE | -98.2% | ||
| Debt/Equity | 0 |
SNSE Forecast & Estimates
9 analysts have analysed SNSE and the average price target is 33.15 USD. This implies a price increase of 292.31% is expected in the next year compared to the current price of 8.45.